Curcumin has well-known, explicit biological anti-tumor properties. The Wnt/b-catenin signaling pathway plays a central role in tumor cell proliferation and curcumin can regulate the Wnt/b-catenin signaling pathway of several carcinomas. The aim of this study was to investigate the impact of curcumin on the Wnt/b-catenin signaling pathway in human gastric cancer cells.
Background
Despite significant advances in cancer therapy, gastric carcinoma (GC) is still one of the deadliest cancers worldwide. GC occurs as a localized disease but may quickly spread to distant sites through invasion or migration [1] . Various therapeutic strategies are currently available for GC patients, including surgery, chemotherapy, and radiotherapy. Chemotherapy remains the main therapeutic approach for GC patients by preventing tumor invasion and metastasis. However, the mortality rates of GC still remain high because of the failure to effectively kill tumor cells by use of chemotherapy agents. Furthermore, chemotherapy has severe residual chemotherapy-related adverse effects. Finding effective and safe preventive agents to suppress tumor invasion and metastasis is a critical approach to cure the disease or improve quality of life for GC patients.
Recently, biologically active anti-cancer agents from natural products have been a focus of research attention, and many reports have indicated that these agents from natural resources are suitable alternatives for controlling cancers [2] [3] [4] [5] [6] [7] [8] .
Curcumin is a polyphenol compound extracted from the root of Curcuma longa [9] . Curcumin has well-known, explicit biological anti-tumor properties. Many studies have shown that curcumin inhibited the growth of various cancer cells and prevented invasion and metastasis through modulating the activity of oncogenes and tumor-suppressor genes, as well as through signaling pathways. Curcumin can inhibit tumor cell proliferation and induce apoptosis in head and neck squamous cell cancer, breast cancer, prostate cancer, lung cancer, and pancreatic adenocarcinoma [10] [11] [12] [13] [14] [15] [16] . Phase I clinical trials have demonstrated that curcumin has no dose-limited toxicity, and can be safely used in cancer treatment [17] . However, it remains unclear whether curcumin has anti-cancer activity in GC, and the molecular mechanism also needs to be explored.
Studies have reported that curcumin reduces lung inflammation and diabetic renal fibrosis, and alleviates glucocorticoid-induced osteoporosis by targeting Wnt signaling pathways [18] [19] [20] . Curcumin can also inhibit invasion and metastasis of colon cancer cells and proliferation-migration of non-small cell of lung cancer, medulloblastoma, and hepatocellular carcinoma cells through inhibition of the Wnt signaling pathway [21] [22] [23] [24] [25] [26] . Curcumin promotes apoptosis of human endometrial carcinoma cells through the Wnt signaling pathway [27] , which is closely related to tumorigenesis and plays a central role in tumor cell proliferation, but the mechanism is poorly understood [28] . Modulation of the Wnt/b-catenin signaling is highly correlated with tumor cell metabolism [29] , and its activation leads to chemotherapy resistance in several cancers [30, 31] . Therefore, therapies targeting the Wnt/b-catenin signaling mat be effective in inhibiting tumor growth.
The goal of this study was to determine whether human GC cells are sensitive to the anti-cancer activity of curcumin, and to evaluate the role of curcumin in modulating a specific signaling pathway. Our results indicate that curcumin inhibits the growth of GC cells and induces apoptosis through down-regulation of Wnt/b-catenin signaling. Curcumin possesses an explicit anti-cancer ability and could be a candidate for use in gastric cancer treatment. 
Material and Methods

Reagents
Cell lines
The human gastric carcinoma cell lines SNU-1, SNU-5, and AGS were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were cultured in RPMI 1640(SNU-1), Iscove's Modified Dulbecco's Medium (SNU-5), and F-12K Medium (AGS) with 10% fetal bovine serum at 37°C in a 5% CO 2 humidified atmosphere.
Cell viability assay
The MTT assay was performed to determine the cell viability. SNU-1, SNU-5, and AGS cells (1×10 4 cells/well) were seeded into 96-well plates and cultured overnight. Different concentrations of curcumin were added to treat cells for 24 h, 48 h, and 72 h. MTT was added to each well and then dissolved by DMSO. The absorbance value was measured by a multiscanner autoreader (Thermo Fisher Scientific Inc., Waltham, MA, USA). Cell viability curves were generated and 50% inhibition concentration (IC50) values were calculated.
Clonogenic assay
Clonogenic assay was performed to determine the survival of cells treated with curcumin. SNU-1, SNU-5, and AGS cells (1×10 5 cells/well) were seeded into 6-well plates and incubated overnight. After 48-h exposure to different concentrations of curcumin, the viable cells were seeded at 1000 cells/flask and cultured for 2 weeks. The colonies were then fixed and stained with crystal violet (Sigma-Aldrich, St. Louis, MO, USA), and the colonies containing more than 50 cells were scored under an Olympus inverted light microscope (Olympus Corp., Tokyo, Japan).
Apoptosis assay
Annexin V/PI method was used to detect apoptosis. Cells (3×10 5 cells/well) were seeded into 6-well plates and incubated overnight. After treatment with different concentrations of curcumin for 48 h, cells were harvested, trypsinized, and washed. Then the cells were stained with Annexin V and PI for 30 min in the dark. Finally, the samples were evaluated by flow cytometry (Beckman Coulter Inc., Brea, CA, USA).
Western blotting analysis
Cells were treated with different concentrations of curcumin for 48 h, and then harvested and lysed in cell lysis buffer containing Tris-HCl and Triton X-100 to extract total protein. An equal amount of denatured protein was decentralized on SDSpolyacrylamide gel transferred to nitrocellulose membranes. Membranes were blocked with 5% non-fat milk in TBST. Specific primary antibody was added to the membrane and then incubated at 4°C overnight. Then the samples were incubated with horseradish peroxidase-conjugated second antibody at room temperature for 30 min. Protein bands were visualized using ECL reagents (Pierce, Rockford, IL, USA) and detected by ImageQuant LAS 4000 (Pittsburgh, PA, USA).
Tumor formation assay in vivo
Male BALB/c nude mice (4-6 weeks, weighing 18-20 g) were purchased from the Laboratory Animal Center of Zhejiang University (Hangzhou, China). Mice were housed under pathogen-free conditions. Experimental protocols were performed according to the guidelines provided by the National Cancer Institute (NIH, USA). The protocol was approved by the Hangzhou Cancer Hospital Research Ethics Committee. The mouse model of xenograft tumor was established by subcutaneously injecting AGS cells. For xenografts, 10 mice were randomly divided into 2 groups. The curcumin treatment group received gavage administration of curcumin (1 mg/kg) once a day, and the control group received gavage administration of 1 ml normal saline once a day. Tumor volumes and weights were measured after mice were sacrificed, and tumors were fixed in 4% formalin fixative and embedded in paraffin for TUNEL staining and Western blotting.
TUNEL analysis
Apoptosis in the gastric carcinoma xenograft model was detected by the terminal deoxynucleotidyl transferase-dUTP nickend labeling (TUNEL) method. In situ cell death detection kits were used following the manufacturer's instructions. Reactions were examined under an Olympus fluorescence microscope (Olympus Corp., Tokyo, Japan).
Statistical analysis
Data are presented as mean ±SD. Statistical analysis was conducted using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Differences between 2 groups were analyzed by the t test, and multiple groups were analyzed by one-way ANOVA. P<0.05 was considered to indicate a statistically significant difference. 
Results
The cytotoxic effects of curcumin on gastric carcinoma cells MTT assay and clonogenic assay were performed to determine the potential cytotoxic effect of curcumin on gastric carcinoma cells. SNU-1, SNU-5, and AGS cells were treated with various concentrations (from 1 to 32 μM) of curcumin for 24 h, 48 h, and 72 h, respectively. MTT assay showed that curcumin significantly reduced the cell viability of SNU-1, SNU-5, and AGS cells in dose-and time-dependent manners, respectively ( Figure 1 ). The results from clonogenic assay showed that colony formation significantly decreased after curcumin treatment in a dose-dependent manner (Figure 2 ). The data indicated that curcumin has an anti-proliferative effect on gastric carcinoma in vitro.
Curcumin induced apoptosis of gastric carcinoma cells
The Annexin V-FITC/PI assay was performed to investigate whether curcumin inhibited gastric carcinoma cell growth by triggering apoptosis. As shown in Figure 3 , curcumin significantly triggered cell apoptosis in SNU-1, SNU-5, and AGS cells: apoptosis rates were increased from 3.21% in the control group to 18.1% of 8 μM, 30.2% of 16 μM, and 42.8% of 32 μM in curcumin-treated SNU-1 cells. Similar increased apoptosis rates were observed in SNU-5 and AGS cells. These data indicate that curcumin induced apoptosis of gastric carcinoma cells in a dose-dependent manner.
Curcumin down-regulated Wnt/b-catenin signaling
The ability of curcumin to inhibit Wnt/b-catenin signaling in gastric carcinoma cells in vitro was investigated by Western blotting. The results showed that curcumin suppressed the levels of Wnt3a, LRP6, and phospho-LRP6 at Ser1490, b-catenin, phospho-b-catenin at Ser675, and expression of C-myc and Survivin in SNU-1, SNU-5, and AGS cells (Figure 4 ). The anti-tumor and apoptosis-inducing effects of curcumin in the gastric carcinoma xenograft model
The anti-tumor activity of curcumin was investigated in vivo by using AGS xenografts. The results showed that tumor volumes and weight were reduced significantly after curcumin treatment ( Figure 5 ). TUNEL assay was performed to analyze the apoptosis induced by curcumin by counting positively labeled cells in random microscopic fields. As shown in Figure 6 , the apoptotic index of the curcumin treatment group was significantly different from that in the control group. Western blotting analysis of in vivo samples also showed that the expressions of Wnt3a, LRP6, phospho-LRP6 (Ser1490), b-catenin, phosphob-catenin (Ser675), C-myc, and survivin were decreased significantly after curcumin treatment ( Figure 7 ). 
Discussion
GC usually easily transforms to the advanced stage, and the overall survival is poor because GC is difficult to cure. Establishment of molecular therapeutic strategies is required to increase survival of GC patients. The Wnt/b-catenin signaling pathway is important for the initiation, progression, and prognosis of human cancers. The b-catenin protein is multifunctional and plays a vital role in the canonical Wnt/b-catenin pathway [32] . It is activated by Wnt signaling, which prevails in different types of signal transduction. Previous studies reported that silencing of b-catenin inhibited cell growth in colorectal cancer, glioblastoma, lung cancer, and ovarian cancer cells in in vitro studies [33] [34] [35] [36] , indicating that b-catenin is essential for cancer growth.
Recent evidence indicates that selectively targeting oncogenic proteins via degradation may be an ideal approach for developing anti-tumor agents. Therefore, Wnt/b-catenin signaling could serve as a good biomolecular target for GC treatment. The potential of curcumin to treat GC has been demonstrated in numerous studies [37] [38] [39] [40] [41] [42] . However, until now there has been no evidence supporting the value of targeting Wnt/b-catenin signaling in use of curcumin to treat GC. The present study demonstrates that curcumin inhibits tumor growth and apoptosis of GC in vitro and in vivo. Furthermore, evidence shows that the mechanism is associated with inhibition of Wnt/bcatenin signaling and reduced expression of Wnt target genes. First, we demonstrated that curcumin exerts its anti-proliferative and pro-apoptotic effect in 3 GC cell lines in a dose-dependent manner. Results from the in vitro effect of curcumin on GC encouraged us to establish an in vivo xenograft model for further study. Curcumin treatment resulted in inhibition of tumor growth compared to control. Next, we analyzed the molecular mechanism of curcumin on GC in vitro and in vivo. We observed reduced Wnt3a, b-catenin, and LRP6 levels, and blocking of b-catenin and LRP6-phosphorylation by curcumin.
LRP6 phosphorylation is critical for the activation of the Wnt/bcatenin signaling pathway [43] . The downstream target genes of the Wnt/b-catenin pathway, such as C-myc and Survivin, are also related to tumor growth, invasion, and metastasis. C-myc is the target oncogene in Wnt/b-catenin signaling and is activated in most human malignancies. C-myc may participate in the regulation of cell proliferation, cell cycle progression, and migration [44] . Survivin, which is another transcriptional target of the Wnt/b-catenin signaling pathway, inhibits caspase activation, thereby leading to negative regulation of apoptosis [45] . Our results showed that the expressions of C-myc and Survivin were significantly decreased in the 3 GC cell lines in a dose-dependent manner, as well as in a xenograft model.
The above findings indicate that inhibition of the Wnt/b-catenin signaling pathway might be responsible for the anti-tumor effect of curcumin in human GC. Although further detailed work is necessary to fully elaborate the mechanism of curcumin in GC treatment through the Wnt/b-catenin signaling pathway, the results of present study may provide valuable insights into the anti-tumor activities of curcumin and its relationship with the Wnt/b-catenin signaling pathway.
Conclusions
Our results demonstrate that curcumin exerts anti-proliferative and pro-apoptotic effects in GC cells and in a xenograft model, and remains a potential candidate for GC treatment. Inhibition of the Wnt/b-catenin signaling pathway and the subsequent reduced expression of Wnt target genes might be a molecular mechanism of curcumin treatment.
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